Salsalate

Generic Name
Salsalate
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C14H10O5
CAS Number
552-94-3
Unique Ingredient Identifier
V9MO595C9I
Background

Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In...

Indication

For relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Targeting Inflammation to Treat Cardiovascular Aging

First Posted Date
2013-01-25
Last Posted Date
2018-05-31
Lead Sponsor
Gary L. Pierce
Target Recruit Count
59
Registration Number
NCT01775865
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

Salsalate as an Adjunctive Treatment for Patients With Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Interventions
Drug: salsalate
First Posted Date
2012-04-17
Last Posted Date
2018-05-08
Lead Sponsor
University of Massachusetts, Worcester
Target Recruit Count
17
Registration Number
NCT01578486
Locations
🇺🇸

University of Massaschusetts Medical School, Worcester, Massachusetts, United States

Trial To Evaluate the Efficacy of Oral Salsalate in the Treatment of Older Adults With Unexplained Anemia

Phase 2
Terminated
Conditions
Anemia
Interventions
Drug: Placebo
Drug: Salsalate
First Posted Date
2012-01-10
Last Posted Date
2016-10-18
Lead Sponsor
Harvey Jay Cohen
Target Recruit Count
11
Registration Number
NCT01506726
Locations
🇺🇸

Johns Hopkins University Geriatrics Center, Baltimore, Maryland, United States

🇺🇸

Lakeview Medical Research, Summerfield, Florida, United States

🇺🇸

St Joseph's/Candler Health System, Savannah, Georgia, United States

and more 7 locations

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

Phase 1
Terminated
Conditions
Polycystic Ovary Syndrome
Interventions
Drug: Salsalate
First Posted Date
2011-12-09
Last Posted Date
2017-02-10
Lead Sponsor
Indiana University
Target Recruit Count
47
Registration Number
NCT01489319
Locations
🇺🇸

Indiana University Hospital, Indianapolis, Indiana, United States

Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy

Phase 2
Completed
Conditions
Peripheral Neuropathy
Type 1 Diabetes
Interventions
Drug: Salsalate
First Posted Date
2011-11-28
Last Posted Date
2015-04-24
Lead Sponsor
University of Michigan
Target Recruit Count
8
Registration Number
NCT01480297
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Salsalate for Insulin Resistance in Schizophrenia

Not Applicable
Completed
Conditions
Insulin Resistance
Schizophrenia
Interventions
Drug: salsalate
First Posted Date
2010-08-17
Last Posted Date
2022-03-11
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
13
Registration Number
NCT01182727
Locations
🇺🇸

Baltimore VA Medical Center, Baltimore, Maryland, United States

🇺🇸

Maryland Psychiatric Research Center, Baltimore, Maryland, United States

Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults

First Posted Date
2010-01-12
Last Posted Date
2015-01-07
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
40
Registration Number
NCT01046682
Locations
🇺🇸

University Hospitals Case Medical Center, Cleveland, Ohio, United States

Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II

First Posted Date
2008-12-01
Last Posted Date
2017-12-11
Lead Sponsor
Joslin Diabetes Center
Target Recruit Count
638
Registration Number
NCT00799643
Locations
🇺🇸

Emory University School of Medicine, Atlanta, Georgia, United States

🇺🇸

Kaiser Permanente, Tucker, Georgia, United States

🇺🇸

University of Texas Southwestern, Dallas, Texas, United States

and more 18 locations

Inflammation and Vascular Function in Atherosclerosis

Phase 2
Completed
Conditions
Atherosclerosis
Interventions
Drug: placebo
Drug: salsalate
First Posted Date
2008-09-25
Last Posted Date
2017-05-16
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
58
Registration Number
NCT00760019
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Targeting Inflammation Using Salsalate in CardioVascular Disease

First Posted Date
2008-02-28
Last Posted Date
2019-05-07
Lead Sponsor
Joslin Diabetes Center
Target Recruit Count
340
Registration Number
NCT00624923
Locations
🇺🇸

Joslin Diabetes Center, Boston, Massachusetts, United States

🇺🇸

Heart Center of Metrowest, Framingham, Massachusetts, United States

🇺🇸

Seacoast Cardiology, York, Maine, United States

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy